Pharmaceuticals, Biotechnology and Life Sciences
CTI BioPharma has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for Trisenox (arsenic trioxide).
Bristol-Myers Squibb on Wednesday said it would present 23 abstracts related to Orencia (abatacept), including new data on the role of biomarkers and MRI in RA patient identification and treatment, at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, Spain.
Twist Bioscience, a company that works with DNA synthesis, and the BioBricks Foundation today announced an agreement to provide 10,000 genes to the synthetic biology community.
TiGenix has entered into a partnerships with the largest patient advocacy groups focused on Crohn’s disease and ulcerative colitis in the United States (US) and Europe.
Sanofi has launched a stock purchase plan for its employees to connect them with its future development of the company.
Baxter International has entered into an agreement with a global contract research and development (R&D) organization, Dorizoe Lifesciences Limited (Dorizoe), to speed up the development of more than 20 generic injectable products–including anti-infectives, oncolytics and cardiovascular medicines.
South Africa’s competition watchdog has launched an investigation into three drug companies accused of over-charging for cancer medicines, the agency’s chief said on Tuesday.
Results from the CANVAS Program showed Invokana (canagliflozin) compared to placebo actually can reduce combined risk of cardiovascular (CV) death, myocardial infarction (MI), and nonfatal stroke, in patients with type 2 diabetes mellitus (T2DM) at risk for or with a history of CV disease.
A study that was presented at the American Diabetes Association’s Scientific sessions on Monday showed that treatment with autoantigen specific therapies, such as Alum-GAD, is safe to give to children with an increased risk for developing type 1 diabetes, however, it does not prevent the development of the disease.
Boehringer Ingelheim (BI) and Eli Lilly are preparing to investigate Jardiance (empagliflozin) tablets for the treatment of people with chronic kidney disease.